Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A neoplasm with neuroendocrine differentiation that arises from the pancreas. It includes neuroendocrine tumors (low and intermediate grade) and neuroendocrine carcinomas (high grade).
Biomarker and diagnostic research for pancreatic neuroendocrine neoplasm has been reported in the published literature.
8 clinical trials registered, 4 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 2 PHASE3, 2 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT00830557](https://clinicaltrials.gov/study/NCT00830557) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 11:57 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders |
— |
Mayo Clinic |
RECRUITING |
[NCT03375320](https://clinicaltrials.gov/study/NCT03375320) | Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors | PHASE3 | National Cancer Institute (NCI) | UNKNOWN |
[NCT05746182](https://clinicaltrials.gov/study/NCT05746182) | Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms | — | University of California, San Francisco | RECRUITING |
[NCT06592989](https://clinicaltrials.gov/study/NCT06592989) | A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNET | — | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | RECRUITING |
[NCT06202066](https://clinicaltrials.gov/study/NCT06202066) | Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas | PHASE2 | Roswell Park Cancer Institute | UNKNOWN |
254 publications have been identified in PubMed for pancreatic neuroendocrine neoplasm. Research spans Review / Meta-Analysis (31%), Basic Science / Preclinical (16%), and Clinical Trial Publication (14%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 78 | 31% |
Laboratory research | 41 | 16% |
Clinical study results | 36 | 14% |
Patient case studies | 34 | 13% |
Disease patterns and progression | 30 | 12% |
Testing and diagnosis research | 29 | 11% |
New treatment approaches | 4 | 2% |
Other research | 2 | 1% |
Duan S (2026). [PMID: 41723447](https://pubmed.ncbi.nlm.nih.gov/41723447/). *Mol Cancer*. [Basic Science / Preclinical]
Gao C (2026). [PMID: 42108362](https://pubmed.ncbi.nlm.nih.gov/42108362/). *Ann Surg Oncol*. [Diagnostic / Biomarker]
Stevens KJ (2026). [PMID: 31613505](https://pubmed.ncbi.nlm.nih.gov/31613505/). *Unknown Journal*. [Diagnostic / Biomarker]
Omotosho YB (2026). [PMID: 41498210](https://pubmed.ncbi.nlm.nih.gov/41498210/). *J Clin Endocrinol Metab*. [Epidemiology / Natural History]
Ergenç M (2026). [PMID: 41998800](https://pubmed.ncbi.nlm.nih.gov/41998800/). *Cancer Control*. [Diagnostic / Biomarker]
Yang TY (2026). [PMID: 42067846](https://pubmed.ncbi.nlm.nih.gov/42067846/). *BMC Surg*. [Case Report / Case Series]
Zhou Y (2026). [PMID: 42147920](https://pubmed.ncbi.nlm.nih.gov/42147920/). *Quant Imaging Med Surg*. [Diagnostic / Biomarker]
Colorado-Yohar SM (2026). [PMID: 41783447](https://pubmed.ncbi.nlm.nih.gov/41783447/). *Frontiers in oncology*. [Epidemiology / Natural History]
Song H (2026). [PMID: 41553527](https://pubmed.ncbi.nlm.nih.gov/41553527/). *Abdominal radiology (New York)*. [Clinical Trial Publication]
Früh O (2026). [PMID: 42210668](https://pubmed.ncbi.nlm.nih.gov/42210668/). *Compr Physiol*. [Basic Science / Preclinical]
AI-curated news mentioning pancreatic neuroendocrine neoplasm
Updated Jun 15, 2026
A study published in PubMed explores the use of robotic subtotal pancreatectomy for treating multifocal neuroendocrine tumors of the pancreas. This surgical approach may enhance recovery and reduce complications compared to traditional methods.
A recent study identifies significant intra-pancreatic fat deposition as an independent prognostic factor in high-grade pancreatic neuroendocrine neoplasms. This discovery could influence future research and treatment strategies for this rare cancer type.
A case study highlights the use of conversion surgery for a pancreatic neuroendocrine neoplasm complicated by tumor seeding-related peritoneal dissemination following a biopsy. This research contributes to understanding surgical interventions in complex cases of neuroendocrine tumors.